Navigation Links
HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
Date:5/10/2013

FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013.  The conference is being held May 14-16, 2013 at the Encore at Wynn in Las Vegas.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 30 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
2. HeartWare Schedules First Quarter Conference Call And Webcast
3. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
4. HeartWare International, Inc. Announces Public Offering of Common Stock
5. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
6. HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
7. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
8. HeartWare Schedules Fourth Quarter Conference Call and Webcast
9. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
10. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
11. HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
(Date:7/7/2015)... ... July 07, 2015 , ... ... Purdy as the company’s new Chief Financial Officer, effective July 6th, 2015. Ellen ... in companies ranging from a multi-billion dollar, global chemical company to early and ...
(Date:7/7/2015)... ... 2015 , ... RadSite™, a leading accreditation agency for diagnostic ... Medicare and Medicaid Services (CMS), announces that it has updated its website for ... most effective websites are those that provide timely information, frequent updates and a ...
(Date:7/7/2015)... ... 07, 2015 , ... On May 29, 2015, Health Canada announced that they ... gluten-free claims for gluten free oats and foods that contain them as ingredients. , ... (GFCP) to include gluten-free oat products in Canada,” says Frank Massong, VP of ...
(Date:7/7/2015)... ... 2015 , ... CareSync proudly announces today that Amy Gleason, ... House as a “Champion of Change” for Precision Medicine on Wednesday, July 8th. ... Change program recognizes Gleason and eight other extraordinary individuals who are making great ...
(Date:7/6/2015)... ... July 06, 2015 , ... For over twenty years, Doctors on Liens ... Throughout the company’s history the goal has been to be a comprehensive network ... recovery. And while Doctors on Liens has certainly achieved that goal, the addition ...
Breaking Medicine News(10 mins):Health News:Office Practicum Announces new CFO 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... ... month of February, sports’ betting was the third most frequently cited primary problem experienced ... Super Bowl and the Kentucky Derby have a substantial effect on sports bettors in ... , ...
... ... ... a workforce solutions company placing health care professionals in contract assignments at hospitals ... Janet S. Elkin as President and Chief Executive Officer of the Park City, Utah ...
... ... in Hospital Medicine designation. , ... (PRWEB) March 12, 2010 -- The Society of Hospital Medicine (SHM) has announced that Dr. ... who have earned the first-ever Senior Fellow in Hospital Medicine (SFHM) designation. Along with other ...
... ... , ... ... NEW YORK , March 12 In releasing a new report on maternal health nationwide, Amnesty ...
... ... , ... ... NEW YORK , March 12 In releasing a new report on maternal health nationwide, Amnesty International today revealed that ...
... of Women Live in a Medically Underserved Area , ... , , ... ... NEW YORK , March 12 ...
Cached Medicine News:Health News:It's March Madness and the Florida Council on Compulsive Gambling Reminds Fans they don't have to Wager to Enjoy the Game 2Health News:Supplemental Health Care Names New Leader 2Health News:Supplemental Health Care Names New Leader 3Health News:Senior Fellow in Hospital Medicine 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; California 35th Among All States in Maternal Mortality 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; California 35th Among All States in Maternal Mortality 3Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; California 35th Among All States in Maternal Mortality 4Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; California 35th Among All States in Maternal Mortality 5Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; California 35th Among All States in Maternal Mortality 6Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; California 35th Among All States in Maternal Mortality 7Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Mississippi is 45th Among All States in Maternal Mortality 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Mississippi is 45th Among All States in Maternal Mortality 3Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Mississippi is 45th Among All States in Maternal Mortality 4Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Mississippi is 45th Among All States in Maternal Mortality 5Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Mississippi is 45th Among All States in Maternal Mortality 6Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Mississippi is 45th Among All States in Maternal Mortality 7Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Georgia is 50th Among All States in Maternal Mortality 2Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Georgia is 50th Among All States in Maternal Mortality 3Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Georgia is 50th Among All States in Maternal Mortality 4Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Georgia is 50th Among All States in Maternal Mortality 5Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Georgia is 50th Among All States in Maternal Mortality 6Health News:New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Georgia is 50th Among All States in Maternal Mortality 7
... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
e-MDs Bill practice management system is used in the medical billing cycle....
Medicine Products: